Profil
S.
George Simon is currently working as a Director at Omixon Biocomputing Kft.
Prior to this, he worked as the President & Chief Executive Officer at MediProPharma, Inc. He also worked as the Vice President-Business Development at Myriad Genetics, Inc. and Tute Genomics, Inc.
Postes actifs de S. George Simon
| Sociétés | Poste | Début |
|---|---|---|
Omixon Biocomputing Kft
Omixon Biocomputing Kft Medical SpecialtiesHealth Technology Operates molecular diagnostics company that develops and commercializes disruptive technologies for clinical & research laboratories | Directeur/Membre du Conseil | - |
Anciens postes connus de S. George Simon
| Sociétés | Poste | Fin |
|---|---|---|
MediProPharma, Inc.
MediProPharma, Inc. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Directeur Général | - |
Tute Genomics, Inc.
Tute Genomics, Inc. Packaged SoftwareTechnology Services Develops and provides cloud-based application that delivers genomic insights to genetics research, clinicians and medical practitioners | Corporate Officer/Principal | - |
| MYRIAD GENETICS, INC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Myriad Genetics, Inc.
Myriad Genetics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic and predictive medicine products | Health Technology |
Tute Genomics, Inc.
Tute Genomics, Inc. Packaged SoftwareTechnology Services Develops and provides cloud-based application that delivers genomic insights to genetics research, clinicians and medical practitioners | Technology Services |
MediProPharma, Inc.
MediProPharma, Inc. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
Omixon Biocomputing Kft
Omixon Biocomputing Kft Medical SpecialtiesHealth Technology Operates molecular diagnostics company that develops and commercializes disruptive technologies for clinical & research laboratories | Health Technology |
















